Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $160.97 +25.85 (+19.13%) (As of 11/13/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Natera Stock (NASDAQ:NTRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Natera alerts:Sign Up Key Stats Today's Range$152.00▼$167.7950-Day Range$112.90▼$160.9752-Week Range$49.97▼$167.79Volume4.52 million shsAverage Volume1.33 million shsMarket Capitalization$19.91 billionP/E RatioN/ADividend YieldN/APrice Target$135.06Consensus RatingBuy Company OverviewNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More… Is AI Hype Hiding the Big Picture? (Ad)Jeff Bezos has loaded up on a tiny company being called "the Next Nvidia." If you've never heard of what I call "QaaS" technology, you need to see this now.Click here and get the details now. Natera Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreNTRA MarketRank™: Natera scored higher than 58% of companies evaluated by MarketBeat, and ranked 509th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.96) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -91.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -91.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 25.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Natera has recently decreased by 1.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.01% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Natera has recently decreased by 1.59%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment0.98 News SentimentNatera has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Natera this week, compared to 8 articles on an average week.Search Interest11 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows8 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,849,977.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Stock News Headlines3 Under-the-Radar Healthcare Companies (NTRA)While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.November 11 at 8:00 AM | marketbeat.comNatera, Inc. (NASDAQ:NTRA) CFO Sells $235,955.70 in StockNovember 2, 2024 | insidertrades.comWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…November 14, 2024 | Investors Alley (Ad)Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,196 SharesOctober 31, 2024 | insidertrades.comMichael Burkes Brophy Sells 691 Shares of Natera, Inc. (NASDAQ:NTRA) StockOctober 26, 2024 | insidertrades.comCraig-Hallum Remains a Buy on Natera (NTRA)November 14 at 2:23 AM | markets.businessinsider.comNatera Stock Explodes 20% After Record-Breaking Q3--Is This Biotech Giant Just Getting Started?November 13 at 5:26 PM | finance.yahoo.comNatera’s Strong Financial Performance and Growth Potential Justify Buy RatingNovember 13 at 5:26 PM | markets.businessinsider.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA stock has increased by 157.0% and is now trading at $160.97. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings data on Tuesday, November, 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm's quarterly revenue was up 63.9% compared to the same quarter last year. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Top institutional shareholders of Natera include Massachusetts Financial Services Co. MA (2.01%), Allspring Global Investments Holdings LLC (0.99%), Principal Financial Group Inc. (0.82%) and Charles Schwab Investment Management Inc. (0.65%). Insiders that own company stock include Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, John Fesko, Solomon Moshkevich, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Gail Boxer Marcus, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings11/12/2024Today11/14/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$135.06 High Stock Price Target$175.00 Low Stock Price Target$70.00 Potential Upside/Downside-16.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-14.01% Pretax Margin-21.35% Return on Equity-26.88% Return on Assets-14.55% Debt Debt-to-Equity Ratio0.34 Current Ratio4.14 Quick Ratio4.01 Sales & Book Value Annual Sales$1.08 billion Price / Sales18.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book25.27Miscellaneous Outstanding Shares123,680,000Free Float114,281,000Market Cap$19.91 billion OptionableOptionable Beta1.53 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:NTRA) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThis “IRS Loophole” Allows You to Do WHAT?Little-Known IRS Loophole Beats Inflation 4x Over New guide reveals how to take advantage of this federally...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.